drugset / Trial / NCT00463385
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with myeloid metaplasia (MMM).
Timeline
- Start
- 2007-04-01
- Primary completion
- 2009-05-01
- Completion
- 2013-12-31
Publications
- Background Barosi G, et al. Decrease Of T Regulatory Cells In Patients With Myelofibrosis Receiving Ruxolitinib. Presented at American Society of Hematology 2013, December 7-10, 2013, New Orleans, LA. Abstract No. 4057. Blood, 2013;122(21)
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pomalidomide | Other / unclassified | 0.5 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 2 mg | Oral |
| Subject | Prednisone | Other / unclassified | 15 mg | Oral |